Skip to main content

MSN - GLP-1 receptor agonists used in the management of type 2 diabetes

Medicine Supply Notification

GLP-1 receptor agonists* used in the management of type 2 diabetes


Tier 3 – high impact**

Date of issue: 27/06/2023

Link: Medicines Supply Tool


There are very limited, intermittent supplies of all glucagon-like peptide-1 receptor agonists (GLP-1 RAs) licensed in the management of Type 2 Diabetes Mellitus (T2DM). Supply is not expected to return to normal until at least mid-2024. The supply issues have been caused by an increase in demand for these products for licensed and off-label indications. Please refer to the SPS Tool for Medicines Shortages for an up-to-date supply stock situation and clinical guidance on alternative treatment options.

Download MSN.

*Annex 4 lists individual medicines affected

**Classification of Tiers can be found at this link